<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334360</url>
  </required_header>
  <id_info>
    <org_study_id>Dexmed/Buspirone</org_study_id>
    <nct_id>NCT00334360</nct_id>
  </id_info>
  <brief_title>Dexmed/Buspirone Synergism on Shivering</brief_title>
  <official_title>Do Dexmedetomidine and Buspirone Synergistically Reduce the Threshold, Gain, and Maximum Intensity of Shivering?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine if the combination of buspirone and
      dexmedetomidine are effective as a treatment to induce therapeutic hypothermia.

      The design of the study includes four study days done in random order. The days are as
      follows: 1) Control (no drug); 2) Buspirone 60 mg orally; 3) Dexmedetomidine (delivered by a
      computer-controlled IV infusion to a target plasma concentration of 0.6 ng/ml); and, 3) the
      combination of buspirone 60 mg and dexmedetomidine (target plasma concentration of 0.6
      ng/ml). a 20 cm-long catheter will be inserted into a cubital vein using standard aseptic
      technique In addition to the PIC line catheter, a simple peripheral catheter will be inserted
      into the other arm for drug administration.

      Throughout the study period, mean-skin temperature will be maintained at 31°C by adjusting
      the temperature of circulating water (Cincinnati Sub-Zero, Cincinnati, OH) and forced-air
      warmers (Augustine Medical, Inc., Eden Prairie, MN). Furthermore, the back, upper-body, and
      lower-body will individually be maintained at the designated skin temperature. Lactated
      Ringer's solution cooled to ≈3°C will be infused via the PIC-line at rates sufficient to
      decrease tympanic membrane temperature ≈1.5°C/h. Fluid will be administered as long as oxygen
      consumption or electromyographic intensity (see below) continues to increase or a total of 5
      liters of fluid is given. Heart rate will be measured continuously using an
      electrocardiogram; blood pressure will be determined oscillometrically at 5 min intervals at
      the ankle. In case heart rate and/or blood pressure changes unexpectedly (by more than 30% of
      the baseline), the study will stop and the volunteer will be re-warmed immediately.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Shivering threshold</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum intensity of shivering</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>gain of shivering</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemodynamic responses</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Hypothermia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buspirone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buspirone and dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buspirone</intervention_name>
    <description>Buspirone, 60 mg orally, will be given during controlled hypothermia.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bus and Dex</intervention_name>
    <description>the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No drugs given during controlled hypothermia</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-40 years

          -  normal weight (BMI &lt;35)

          -  healthy

        Exclusion Criteria:

          -  obese (BMI &gt;35)

          -  taking any drugs

          -  thyroid disease, dysautonomia, or Raynaud's syndrome

          -  severe claustrophobia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Lenhardt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Outcomes Research Institute, University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2006</study_first_submitted>
  <study_first_submitted_qc>June 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2006</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

